Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
EVEvofem Biosciences, Inc. logo

Evofem Biosciences, Inc. (EVFM)

Other OTC · Currency in USD
$0.01 ▲ +0.00 (+9.38%)
At close: Oct 23, 4:00 PM ET. Market closed.

Summary

Previous Close
$0.01
Open
$0.01
Day's Range
$0.01 – $0.01
52 Week Range
$0.00 – $0.02
Volume
108
Avg. Volume
209,094
Market Cap
$927.71K
Beta (5Y Monthly)
-1.36
PE Ratio (TTM)
--
EPS (TTM)
-$0.11
Earnings Date
Nov 12, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$66.25

Profile: Evofem Biosciences, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
29
CEO
Saundra Pelletier
Website
evofem.com

Evofem Biosciences, Inc. operates as a biopharmaceutical enterprise dedicated to innovating and bringing to market treatments that address critical underserved areas in women's sexual and reproductive health. Their leading commercial offering is Phexxi, a vaginal gel specifically designed as a contraceptive. Additionally, the company is actively advancing EVO100, an antimicrobial vaginal gel under development, intended to prevent the urogenital spread of both Chlamydia trachomatis and Neisseria gonorrhoeae infections in women.

Earnings

Next report: Thu, Nov 12, 2026
EPS estimate -$914.06 · Revenue est. $1.69M
DateEst.Actual
Aug 14, 2026-$914.06-$0.06Beat
May 15, 2026-$914.06-$0.04Beat
Mar 11, 2026–-$0.03
Nov 13, 2025–-$0.01
Aug 14, 2025–-$0.02
May 15, 2025–-$0.16

Analyst view

Consensus price target
$66.25 ▲ +946,328.6%
Range $66.25 – $66.25
Rating: Buy
Buy 78% · Hold 11% · Sell 11%

Get free alerts on EVFM and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.